FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740431114> ?p ?o ?g. }

• W2740431114 endingPage "240" @default.
• W2740431114 startingPage "233" @default.
• W2740431114 abstract "Targeted therapies that act via unique molecular pathways and interfere with cancer cell growth and tumor progression have dramatically changed the cancer treatment paradigm. However, although, ideally, these therapies intend to target only cancer cells, they do often affect nonmalignant tissue. Numerous renal side effects have been reported to date. This article will review clinical presentation, presumed pathophysiology, and treatment of kidney side effects of targeted therapies. Feasibility of the continuation of cancer therapy despite renal toxicity will also be addressed. Targeted therapies that act via unique molecular pathways and interfere with cancer cell growth and tumor progression have dramatically changed the cancer treatment paradigm. However, although, ideally, these therapies intend to target only cancer cells, they do often affect nonmalignant tissue. Numerous renal side effects have been reported to date. This article will review clinical presentation, presumed pathophysiology, and treatment of kidney side effects of targeted therapies. Feasibility of the continuation of cancer therapy despite renal toxicity will also be addressed. Clinical Summary•Novel targeted cancer therapies are associated with a variety of kidney complication, for example-Immune check point inhibitors cause activation of innate immune system leading to acute interstitial nephritis.•Proteinuria, hypertension, and, in more severe cases, thrombotic microangiopathy have been associated with antiangiogenic therapies.•Epithelial growth factor pathway inhibition may lead to hypomagnesemia due to decreased renal distal reabsorption.•In selected patients, it is feasible to continue targeted therapies despite the development of adverse kidney reactions, and in most patients, the side effects resolve after withdrawal of the offending agent. •Novel targeted cancer therapies are associated with a variety of kidney complication, for example-Immune check point inhibitors cause activation of innate immune system leading to acute interstitial nephritis.•Proteinuria, hypertension, and, in more severe cases, thrombotic microangiopathy have been associated with antiangiogenic therapies.•Epithelial growth factor pathway inhibition may lead to hypomagnesemia due to decreased renal distal reabsorption.•In selected patients, it is feasible to continue targeted therapies despite the development of adverse kidney reactions, and in most patients, the side effects resolve after withdrawal of the offending agent." @default.
• W2740431114 created "2017-08-08" @default.
• W2740431114 creator A5053243066 @default.
• W2740431114 creator A5059248910 @default.
• W2740431114 date "2017-07-01" @default.
• W2740431114 modified "2023-10-01" @default.
• W2740431114 title "Kidney Toxicities Associated With Novel Cancer Therapies" @default.
• W2740431114 cites W1592490662 @default.
• W2740431114 cites W1965024282 @default.
• W2740431114 cites W1978432535 @default.
• W2740431114 cites W1979068418 @default.
• W2740431114 cites W1982983286 @default.
• W2740431114 cites W1986841387 @default.
• W2740431114 cites W1989679369 @default.
• W2740431114 cites W1997619520 @default.
• W2740431114 cites W1999009908 @default.
• W2740431114 cites W2010121426 @default.
• W2740431114 cites W2012297418 @default.
• W2740431114 cites W2014796001 @default.
• W2740431114 cites W2017169228 @default.
• W2740431114 cites W2018760657 @default.
• W2740431114 cites W2027671567 @default.
• W2740431114 cites W2028031291 @default.
• W2740431114 cites W2029323837 @default.
• W2740431114 cites W2046846997 @default.
• W2740431114 cites W2048818094 @default.
• W2740431114 cites W2051204558 @default.
• W2740431114 cites W2060587247 @default.
• W2740431114 cites W2072136531 @default.
• W2740431114 cites W2074937425 @default.
• W2740431114 cites W2075391935 @default.
• W2740431114 cites W2078222208 @default.
• W2740431114 cites W2089311432 @default.
• W2740431114 cites W2096322385 @default.
• W2740431114 cites W2100327051 @default.
• W2740431114 cites W2101027485 @default.
• W2740431114 cites W2101653483 @default.
• W2740431114 cites W2104218654 @default.
• W2740431114 cites W2111092101 @default.
• W2740431114 cites W2111346120 @default.
• W2740431114 cites W2115125611 @default.
• W2740431114 cites W2116259155 @default.
• W2740431114 cites W2117005806 @default.
• W2740431114 cites W2118034103 @default.
• W2740431114 cites W2119404465 @default.
• W2740431114 cites W2124495521 @default.
• W2740431114 cites W2126125759 @default.
• W2740431114 cites W2126453999 @default.
• W2740431114 cites W2128708846 @default.
• W2740431114 cites W2132776347 @default.
• W2740431114 cites W2134787029 @default.
• W2740431114 cites W2137467802 @default.
• W2740431114 cites W2138184118 @default.
• W2740431114 cites W2157027198 @default.
• W2740431114 cites W2167646314 @default.
• W2740431114 cites W2167798736 @default.
• W2740431114 cites W2168864333 @default.
• W2740431114 cites W2223436478 @default.
• W2740431114 cites W2293531514 @default.
• W2740431114 cites W2295766629 @default.
• W2740431114 cites W2298050501 @default.
• W2740431114 cites W2303235652 @default.
• W2740431114 cites W2306401151 @default.
• W2740431114 cites W2338242614 @default.
• W2740431114 cites W2341933843 @default.
• W2740431114 cites W2413514895 @default.
• W2740431114 cites W2416137380 @default.
• W2740431114 cites W2465928371 @default.
• W2740431114 cites W2468906758 @default.
• W2740431114 cites W2510686645 @default.
• W2740431114 cites W2529221862 @default.
• W2740431114 cites W2555713829 @default.
• W2740431114 cites W2578082697 @default.
• W2740431114 cites W2582295359 @default.
• W2740431114 doi "https://doi.org/10.1053/j.ackd.2017.05.006" @default.
• W2740431114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28778363" @default.
• W2740431114 hasPublicationYear "2017" @default.
• W2740431114 type Work @default.
• W2740431114 sameAs 2740431114 @default.
• W2740431114 citedByCount "14" @default.
• W2740431114 countsByYear W27404311142018 @default.
• W2740431114 countsByYear W27404311142019 @default.
• W2740431114 countsByYear W27404311142020 @default.
• W2740431114 countsByYear W27404311142021 @default.
• W2740431114 countsByYear W27404311142022 @default.
• W2740431114 countsByYear W27404311142023 @default.
• W2740431114 crossrefType "journal-article" @default.
• W2740431114 hasAuthorship W2740431114A5053243066 @default.
• W2740431114 hasAuthorship W2740431114A5059248910 @default.
• W2740431114 hasConcept C121608353 @default.
• W2740431114 hasConcept C126322002 @default.
• W2740431114 hasConcept C2780091579 @default.
• W2740431114 hasConcept C2781068499 @default.
• W2740431114 hasConcept C2781230642 @default.
• W2740431114 hasConcept C60644358 @default.
• W2740431114 hasConcept C71924100 @default.
• W2740431114 hasConcept C86803240 @default.
• W2740431114 hasConceptScore W2740431114C121608353 @default.

• next